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Summary A member of the high molecular weight glycoproteins of human milk and breast cancer was
isolated from the sera, ascites and breast carcinoma tissue of patients with breast cancer using monoclonal
antibody 3E1.2. The 3E1.2 defined antigen, termed mammary serum antigen (MSA) was obtained by
immunoaffinity chromatography and a solid phase immuno-precipitation technique (SPIT) from serum of
patients with metastatic breast cancer. MSA was found to be a high molecular weight glycoprotein with a
Mr>300,000 by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and a native
M,r 1 x 106 by gel filtration chromatography; in accord with the published Mr of other high molecular weight
glycoproteins obtained from human milk and breast cancer. A high degree of glycosylation of MSA molecule
was shown by its poor staining with Coomassie blue but good staining in a PAS-silver stain. In addition, MSA
contained N-acetyl neuraminic acid and N-acetyl glucosamine as indicated by its binding to wheat-germ
agglutinin. The epitope defined by antibody 3E1.2 is sensitive to treatment by sodium periodate and
neuraminidase, implying that both carbohydrate and sialic acid are required for binding of antibody 3E1.2.
Sandwich immunoassays demonstrated that MSA+ molecules are likely to express repeated 3E1.2 defined
epitopes. Furthermore, MSA was susceptible to degradation by pronase, subtilisin and proteinase K and gave
a different peptide profile from that of the PAS-O glycoprotein of human milk. MSA+ molecules were found
to carry epitopes for a number of other monoclonal antibodies which were reactive with the PAS-O
glycoprotein. It is suggested that MSA has the same core protein as is recognised by antibody DF3 which has
been used to clone the same cDNA as was cloned with antibodies HMFG-1, HMFG-2 and SM-3. However,
the epitope detected by the 3E1.2 antibody is either absent or weakly expressed on human milk, human milk-
fat globule membrane (HMFGM) or deglycosylated HMFGM - all of which react strongly with various anti-
HMFG antibodies. The antibody 3E1.2 thus recognises a unique epitope of the high molecular weight
glycoproteins of human milk and breast cancer, being found in cancer tissue, serum and ascitic fluid of
patients with breast cancer but weakly expressed or- absent in human milk.
Murine monoclonal antibody 3E1.2, produced by a
hybridoma derived from spleen cells of a mouse immunised
with a human primary breast carcinoma, has demonstrated
selective reactivity with >90% breast carcinoma tissues and
limited reactivity with normal breast tissue and other normal
secretory epithelium (Stacker et al., 1985). The antigen
defined by 3E1.2 (called mammary serum antigen or MSA)
has also been detected in serum, with elevated levels in a
high proportion of patients with localised (-75%) or
disseminated (-90%) breast cancer (Tjandra et al., 1988).
Studies have shown that levels of MSA are useful for
monitoring patients with breast cancer; the antibody has also
been used to localise metastases in axillary lymph nodes in
patients with breast cancer by immunoscintigraphy
(Thompson et al., 1984).
A number of monoclonal antibodies have been described
which react with breast cancer associated antigens and have
tissue distribution similar to 3E1.2 (Arklie et al., 1981; Ellis
et al., 1984; Hilkens et al., 1984; Kufe et al., 1984; Papsidero
et al., 1983). Most of these antibodies have been shown to
detect circulating antigens in the serum of patients with
advanced breast cancer but the detection in localised breast
cancer has been poor (Burchell et al., 1984; Dhokia et al.,
1986; Hayes et al., 1985; Hilkens et al., 1984, 1986; Kufe et
al., 1984). All of these monoclonal antibodies define antigens
which have common biochemical characteristics:
glycoproteins of high molecular weight (M,>300,000 by
SDS-PAGE) with extensive 0-linked carbohydrate side
chains, i.e. mucin-like. In addition these monoclonal
antibodies also react with human milk and human milk-fat
globule membrane (HMFGM) and some antibodies have
been shown to react with the PAS-O glycoprotein from
human milk which is the one human tumour associated
mucin glycoprotein bearing human tumour associated
epitopes (Shimizu et al., 1982; Ormerod et al., 1985). The
Correspondence: I.F.C. McKenzie.
PAS-0 component has also been referred to as EMA
(epithelial membrane antigen) complex (Ormerod et al.,
1983, 1985) and recently popularised as human PEM (poly-
morphic epithelial mucin) (Taylor-Papadimitriou et al., 1988)
because of the genetic polymorphism exhibited.
The purpose of this study was to isolate 3E1.2 antigen
(MSA) from the serum, ascitic fluid and breast cancer tissue
of patients with breast cancer, define its biochemical
structure and investigate its relationship to previously
described breast cancer associated antigens. MSA was found
to be a novel variant of the high molecular weight glyco-
proteins of human breast cancer, as monoclonal antibody
3E1.2 does not react with components of human milk.
Materials and methods
Monoclonal antibodies
Mouse monoclonal antibody 3E1.2 (anti-MSA) was used to
immunopurify MSA in this study. The antibody is a
pentameric 1gM raised against human breast cancer cells
derived from a primary carcinoma of the breast (Stacker et
al., 1985). Control antibodies used were 5C1 (anti-carcinoma
of the colon), 3B1l1C8 (anti-carcinoma of the lung) and 676
(anti-human CD8) (produced in our laboratory). All of these
antibodies were of the p heavy chain isotype and were made
in our laboratory. The following anti-human milk fat globule
membrane antibodies were employed: HMFG-1 (IgGl),
kindly supplied by Dr J. Taylor-Papadimitriou, ICRF,
London (Taylor-Papadimitriou et al., 1981), BC2 (IgGI),
BC3 (IgM), 41.3 (IgM), 4B6.1 (IgM) (produced in our
laboratory) and DF3 (IgGl) obtained from a CA 15-3
IRMA kit (Centocor, Malvern, PA, USA), supplied by the
Australian Atomic Energy Commission (Kufe et al., 1984).
The IgM monoclonal antibodies were purified from ascitic
fluid by lipid extraction using freon (1,1,2-trichloro-
trifluorethane, Fluka AG, Buchs, Switzerland) and dialysis
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against 5mM Tris-HCl pH 7.4 at 4°C. The precipitate formed
was collected by centrifugation at 800g for 30min and
resuspended in phosphate buffered saline (PBS), pH 7.4. The
IgG antibodies were purified on protein A-sepharose
(Pharmacia Inc., Piscataway, NJ) as described (Ey et al.,
1978). Purified antibodies (3E1.2 and 4B6.1) were covalently
bound to cyanogen bromide activated Sepharose 4B
(Pharmacia Fine Chemicals, Uppsala, Sweden) at about
3mgml-1 of swollen beads.
Collection of serum samples, ascitic fluid and breast
carcinoma tissue
Serum was obtained from normal subjects and from patients
with metastatic breast cancer, and stored at -70°C. Ascitic
fluid and primary breast carcinoma tissue were also obtained
from one patient who had high circulating MSA level
(>10,000IU). Ascitic fluid was centrifuged at 10,000g for
10min to pellet cell debris and the supernatant stored at
-700C.
Preparation and deglycosylation of human milk fat globule
membrane (HMFGM) and purification of the milk mucin
Crude HMFGM were prepared from fresh human milk
(Jarasch et al., 1977) after ultracentrifugation at l00,OOOg
for 1.5h at 4°C using Beckman L8-70 with an SW-28 rotor.
The pellet was resuspended in 0.3M sucrose, 70mM KCI2,
2mm MgCl2, 1Omm Tris-HCl buffer pH7.4 and stored at
-70°C. 0-linked carbohydrate residues were removed from
the HMFGM glycoproteins by treatment with trifluoro-
methanesulfonic acid (TFMSA) for 1 h at RT (room
temperature) to produce deglycosylated HMFGM (Edge et
al., 1981). The milk mucin was purified from human
skimmed milk by passage through a 4B6.1 affinity column
followed by size exclusion chromatography (Burchell et al.,
1987); the high molecular weight fractions eluted were
pooled and designated PAS-O (Shimizu et al., 1982).
Serological assays
MSA activity in samples was determined by a competitive
enzyme immunoassay (MSA inhibition assay) (Stacker et al.,
1987: Tjandra et al., 1988) In brief, serum and affinity
purified fractions of MSA were used to inhibit the binding
of monoclonal antibody 3E1.2 to a membrane preparation of
ZR75 breast cancer cells which contains MSA, and the
results expressed as arbitrary inhibition units (IU) on a scale
from 1 to 10,000 IU. Patients with advanced breast cancer
have levels of 300-10,000 IU; 98% of normal individuals
have low levels (<300IU). In addition, the anti-HMFG
activity of the monoclonal antibodies were evaluated in a
HMFG binding assay wherein crude HMFGM were coated
on to 96-well flexible PVC plates (Costar) at 25pgml-1 in
carbonate buffer pH9.6 for 1 h at 37°C; non-specific binding
sites were blocked with 1% BSA for 1 h at 37°C, and the
plates washed with PBS pH 7.4/0.05% Tween 20. Purified
antibodies (240ngml -1 to 30Mgml -1) were then reacted
with the solid phase antigens for 2h at 37°C. After removal
of excess antibody, sheep anti-mouse immunoglobulin
conjugated to horseradish peroxidase (Amersham) was
incubated for 3 h at 37°C. The plates were washed again,
and developed using 0.03% ABTS (2.2-azino-di-[3-ethyl-
benzthiazoline] sulphonate)/0.02% H202 in 0.1 M citrate
buffer pH4 and absorbance read at 405 nm using an enzyme
immunoassay plate reader (Titertek Multiscan MC). The
reactivity of antibodies to deglycosylated HMFGM was
similarly determined using wells coated with deglycosylated
HMFGM and the bound antibody detected as for the
HMFGM binding assay. In addition, a sandwich immuno-
assay was used to assess the epitope expression on immuno-
purified MSA: hybridoma ascitic fluid (1/500 in PBS) was
adsorbed to the wells of flexible PVC plates (Costar) at
lOp1well-1 and after incubation at 4°C for 18h, the wells
were washed with washing buffer (PBS pH 7.4/0.05% Tween
20); aliquots of MSA (10p1) or washing buffer alone were
added to the wells and after incubation for 1 h at room
temperature, the wells were washed, 125I-3E1.2 antibody
(105 c.p.m. 10pl1-well-1) added and incubated for 1h at
room temperature. Finally, the wells were washed and the
radioactivity in each well determined.
Purification of 3EJ.2 defined antigen (MSA) from breast
carcinoma tissue, serum and ascites
Breast carcinoma tissue (15g) was homogenised in PBS,
pH7.3 containing 5mM MgCl2 at 4mlgtissue-1 and an
extranuclear membrane (ENM) preparation was isolated as
the 105,000g pellets of 600g supernatants of the homogenate
(Price et al., 1985). The ENM extracts were obtained with
0.5% Nonidet P-40 (NP-40) in 0.1M Tris-HCI, pH7.0 for
30min at 4°C and a soluble extract was obtained following
centrifugation at 105,000g for 60min. 3E1.2 defined antigen
preparations were isolated from detergent (NP-40)
solubilised subcellular membranes from breast carcinoma,
serum containing high levels of MSA (>O0,000 IU) and
ascites by immunoaffinity chromatography using Sepharose-
linked 3E1.2 antibodies. The samples were diluted 1:1 with
PBS pH7.6 containing 5mM iodoacetamide, 2% aprotinin
(Sigma Chemical Co., St Louis, MO, USA) and 0.02%
NaN3 and reacted with 3EI.2-Sepharose beads for 1 h at
4°C. After incubation the beads were packed in a 10ml
column and washed extensively with PBS pH7.6 at 4°C.
Bound MSA was eluted in 1 ml fractions with 1% diethyl-
amine, pH 11.8 at room temperature (RT) and neutralised
with 1M Tris-HCl pH 7.0. Samples were then freeze dried
and tested for activity using the inhibition assay. MSA was
also isolated from serum on wheat germ agglutinin (WGA)-
Sepharose 6MB, followed by elution with 0.7mgml-1 N-
acetyl glucosamine as described elsewhere (Gurd et al.,
1974).
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) and immunoblotting
Samples were analysed by SDS-PAGE (Laemmli, 1970) and
after electrophoresis gels were stained with either 0.2%
Coomassie blue or 0.25% Croci en scarlet followed by
extensive destaining (7% acetic acid for Coomassie blue, 7%
acetic acid/12% ethanol for Croci en scarlet) or by Periodic
acid-Schiff (PAS)-silver stain technique (Dubray et al., 1982).
Gels were then dried under vacuum, and autoradiographed
at -70°C using XAR-5 film (Eastman Kodak, Rochester,
NY, USA) and intensifying screens (DuPont, Wilmington,
DE, USA). Molecular weight markers used were: 200,000
myosin, 116,000 fl-galactosidase, 92,500 phosphorylase b,
66,000 bovine serum albumin, 43,000 ovalbumin (Biorad
Laboratories). Monoclonal antibody immunoblotting
analysis of samples (under reducing conditions) after
fractionation by SDS-PAGE was performed as described
elsewhere (Towbin et al., 1979). Nitrocellulose membranes
(Schleicher and Schuell, Dassel, FRG) were reacted with a
1/5 dilution of tissue culture supernatant containing the
antibody and developed using sheep anti-mouse immuno-
globulin conjugated to horseradish peroxidase (Amersham).
Alternatively, blotted proteins were reacted with 200,000
c.p.m. of radiolabelled DF3, BC3 or control antibody and
then autoradiographed.
Radiolabelling ofproteins and solid phase
immunoprecipitation technique (SPIT)
Iodination of purified MSA with Na 1251 (Amersham
International, Amersham, UK) was catalysed using
lodobeads (Pierce Chemical Co. Inc., Rockford, IL, USA)
(Markwell, 1982). Crude HMFGM was radiolabelled,
solubilised in 2% (w/w) sodium deoxylate, 8 M urea and 1%
(v/v) 2-mercaptoethanol for 30min at 37°C, then centrifuged
at 10,OOOg for 20min. Free 1251 was removed from the
supernatant by chromatography on Sephadex G-25 (PD-10,546 S.A. STACKER et al.
Pharmacia) equilibrated in Tris-HCl buffer (pH 8.0)
containing 100mM NaCl and 10mM sodium deoxycholate.
In the SPIT assay, purified monoclonal antibodies were
coated at 40ygml-1, in a carbonate buffer pH9.6, to 96-well
flexible PVC plates (Costar, Cambridge, MA, USA) for 2h
at 37°C. Excess antibody was removed by washing with
PBS/0.05% Tween 20 and non-specific binding sites blocked
by incubation with 2% normal mouse serum (NMS)/2%
bovine serum albumin (BSA)/PBS for 2h at 37°C. After
washing, iodinated affinity purified MSA in 2% NMS/2%
BSA/PBS pH 7.6 was added to the wells (- 750,000 c.p.m.
per well) and incubated overnight at 4°C. Following this, the
solid phase was washed extensively with PBS/0.05% Tween
20. Plates were dried, cut, and counted in a gamma-counter.
In some cases, radiolabelled MSA was eluted from the solid
phase with 8 M urea/0.0625 M Tris/2.3% SDS/50mM DTT
(Dithiothreitol) and analysed by SDS-PAGE as described.
Periodate and neuraminidase (NE) treatment
Periodate oxidation was performed by treating ZR75
membrane preparation (MSA+), which has been coated on
microtitre plates (Tjandra et al., 1988). Sodium meta-
periodate (Ajax Chemicals, Australia) was added at
concentrations ranging from 10 to 100mm, in a buffer of
50mM sodium acetate, pH4.5 for 2h at 4°C. Wells were
treated with 1% BSA to block non-specific binding sites, and
then tested for antibody 3E1.2 binding by ELISA as
described before. The immunoperoxidase assays on sections
of formalin fixed breast cancer tissues were performed as
previously described (Stacker et al., 1985). The tissue
sections which were subjected to neuraminidase treatment
were incubated with 1 IU per slide neuraminidase (from
Vibrio cholerae, Institut Behring) for 2h at 37°C, after they
had been treated with 0.5% H202 in PBS to remove
endogenous peroxidase activity. After neuraminidase
treatment, the slides were washed, exposed to the
monoclonal antibody (1:10 dilution of tissue culture super-
natant of 1:1,000 diluted mouse ascites fluid) and processed.
Gel filtration chromatography
MSA isolated by affinity chromatography with either anti-
body 3E1.2 or WGA lectin was applied to a 90 x 2.5 cm
Sepharose-6B column (Pharmacia), equilibrated in PBS/
pH7.6 and prewashed with 3.0ml of human stable plasma
protein solution (Commonwealth Serum Laboratories,
Melbourne, Australia) at 200C. Fractions of 1.0ml were
collected and MSA activity determined by the inhibition
assay. The column was calibrated with molecular weight
markers: blue dextran 2 x 106, thyroglobulin 669,000,
aldolase 158,000 and chymotrypsinogen A 25,000
(Pharmacia).
Protease digestion
Radiolabelled MSA and PAS-0 were immunopurified by
3E1.2-Sepharose and 4B6.1-Sepharose beads respectively,
separated by 5% SDS-PAGE, and detected by autoradio-
graphy. The bands containing the relevant material were
excised using a scalpel blade and reswelled in digestion
buffer (10% (v/v) glycerol, 0.1% (w/v) SDS, 0.125M Tris-
HCl, pH6.8). The swelled gel strips were homogenised and
digested for 4h at 37°C with the following enzymes at
concentrations of 5-250 ugml-1: thermolysin (Sigma
Chemical Co.), trypsin (Miles Laboratories, Eckhart, IN,
USA), proteinase K (Boehringer Mannheim, FRG),
Staphylococcus aureus V8 protease (CalBiochem-Behring, La
Jolla, CA, USA), Pronase (Boehringer Mannheim) and
subtilisin (Boehringer Mannheim). Digestions were also
performed with 10mM DTT. Fragments of gels were pelleted
by centrifugation and aliquots of the supernatant containing
the digested protein loaded on to 15% SDS gels and the
peptides detected by autoradiography. In all cases radio-
labelled BSA or immunoglobulin served as a protease
susceptible control substrate.
Results
Isolation of MSA and analysis by SDS-PAGE and
immunoprecipitation
MSA was isolated fron the serum of patients with advanced
breast cancer where it is present in a soluble form and in
relatively large amounts. Serum samples were subjected to
immunoaffinity chromatography with immobilised mono-
clonal antibody 3E1.2, and eluted antigen was analysed by
SDS-PAGE, Coomassie blue staining and PAS-silver
staining (Figure 1), and its activity determined by the
inhibition assay. Although MSA stained poorly with
Coomassie blue (Figure la), it stained well with PAS-silver
stain (Figure lb). Virtually all of the initial MSA activity
was recovered from the antibody column in a single broad
peak; the absence of extraneous bands in SDS-PAGE
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Figure 1 Coomassie blue staining (a) and PAS-silver staining
(b) of 5% SDS-polyacrylamide gels, of serum with MSA level
> 10,000IU (track A), affinity purified MSA (track B) and
HMFGM (track C). Molecular weight markers are as indicated.
S indicates stacking gel. Differences in the intensity of the high
molecular weight bands between serum and affinity purified
MSA in the PAS-silver stain could be accounted for by the
difference in the amount loaded on to the gel.BREAST CANCER ASSOCIATED ANTIGEN 547
analysis (Figure 1) indicated that the preparation was pure.
This does not eliminate, however, the possibility that there
may be contaminants with the same electrophoretic mobility
as MSA. The fractions containing purified material were
pooled, radiolabelled and assayed by a solid phase immuno-
precipitation technique (SPIT) for activity with 3E1.2 and
other isotype matched control antibodies. The 3E1.2 mono-
clonal antibody immune precipitated more than 20 times the
amount of radiolabelled antigen precipitated by the control
antibodies. When these samples were eluted with 8M urea/
SDS sample buffer from the coated wells and analysed by
SDS-PAGE, two discrete bands with Mr values of 300,000-
400,000 were observed (Figure 2a). Identical patterns were
seen under reducing and non-reducing conditions, indicating
that the two molecules are not covalently linked. The 3E1.2
antibody was also reactive with the immunoadsorbent
purified MSA from serum on immunoblots and Figure 2b
(tracks D and E) show the reaction of antibody 3E1.2 with
the dominant Mr300,000-400,000 bands of the MSA.
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Reactivity of 3EL2 antibody with serum, ascites and
extranuclear membrane preparations
Analysis of serum samples from a number of patients with
advanced breast cancer by immunoblotting with 3E1.2
showed a heterogeneous expression of MSA (Figure 3).
Three basic variations were seen: (a) a predominant single
band of approximate Mr380,000 (Figure 3, patient A); (b)
both upper (Mr380,000) and lower (Mr 330,000) bands
(Figure 3, patients B and C); (c) a single lower band
(Mr 330,000) only (Figure 3, patient D). This immuno-
blotting experiment demonstrates that the epitope for 3E1.2
is expressed on both Mr species (Figure 3, patients B and C).
A smaller molecular weight species (Mr70,000-100,000) was
also detected in some patients on immunoblot of SDS-
PAGE-separated serum (Figures 2b and 3), indicating that
the lower molecular weight material also expresses an
epitope reactive with antibody 3E1.2 and may share a
functional as well as immunological relationship with the
high molecular weight material on which many cancer-
related determinants are expressed later. However, the
absence of the low molecular weight species (Mr70,000-
100,000) in the immunopurified MSA on immunoblot
(Figure 2b) suggests that they do not bind to 3E1.2 immuno-
affinity column to any significant extent (Figure 3, tracks D
and E); the reason of which is not entirely clear but it may
indicate that the low molecular weight species are not
exposed in the native state, in the absence of SDS but this is
not proved.
The ascites and ENM preparations from breast carcinoma
tissue of a patient with advanced breast cancer who had a
high circulating MSA level (>10,000) was analysed by the
inhibition assay. Both the ascites and ENM preparations and
strong inhibitory activity (8,000 and 5,000IU respectively).
The nature of the 3E1.2 defined antigen (MSA) in serum,
ascites and ENM preparations of the same patient was
examined by Western blot analysis with 3E1.2 antibody
probe. As shown in Figure 2b, the 3E1.2 defined antigen
(MSA) was identified as a diffusely migrating band of
similar high apparent molecular weight (>300,000),
irrespective of the source of the antigen in the same patient.
The pattern was reproducible on repeated testing with
specimens from other patients and is similar to that obtained
with immunoadsorbent purified MSA from serum when
probed with 3E1.2 antibody (Figure 2b). A faint band of
3E1.2 reactive material of Mr-220,000 was also noted in the
ENM preparation from breast carcinoma tissue.
Clearly, 3E1.2 defined antigen (MSA) present in detergent
solubilised tumour membrane preparations were similar to
3E1.2 defined antigen present in serum and ascites of the
same patient. Similar high molecular weight components
reactive with 3EI.2 antibody in normal sera were not easily
identified by immunoblotting (data not shown).
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Figure 2 Analysis of MSA by SPIT assay, SDS-PAGE, and
immunoblots. In (a) fractions eluted from the immunoaffinity
column that contained MSA activity were pooled, radiolabelled
and used for SPIT assay using various antibodies. The bound
MSA was eluted from the solid phase analysed by 5% SDS-
PAGE. Track A, 3E1.2 (lysate reduced); track B, 3E1.2 (lysate
non-reduced); track C, 5C1; track D, 3BllC8; and track E, 676.
In (b) immunoblotting of ascites (track A), NP-40 solubilised
breast cancer tissue (track B), serum (track C) and 3E1.2 defined
antigen (MSA) isolated from serum by immunoaffinity
chromatography (tracks D and E) was performed; all samples
from the same patient with advanced breast cancer. Samples
were separated by SDS-PAGE, electrophoretically transferred on
to nitrocellulose paper and 'stained' with the 3E1.2 antibody.
Molecular weight marker proteins are as shown.
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Figure 3 Reactivity of monoclonal antibody 3E1.2 with serum
samples from selected patients with metastatic breast cancer was
studied. Sample E was the residual serum sample after mixing
serum sample F with 3E1.2 sepharose beads. Serum (5,ul) was
subjected to 5% SDS-PAGE analysis, transferred to
nitrocellulose paper and probed with 3E1.2. Approximate
molecular weight standards are indicated.
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Biochemical anal sis of MSA
To determine whether carbohydrate structures are required
for binding of the antibodies, the effects of sodium periodate
treatment on antibody binding were tested. Results shown in
Figure 4 indicate that the epitope detected by 3E1.2 was
sensitive to the periodate treatment, suggesting that carbo-
hydrate plays a role in the binding site of 3E1.2. The effect
of neuraminidase treatment on the expression of the antigen
in breast cancer tissues was also studied. The binding of
3E1.2 antibody was markedly diminished by neuraminidase
treatment in all five formalin fixed breast cancer tissues
tested, as assessed by the percentage of carcinoma cells
stained and the intensity of staining on immunoperoxidase
assay (Figure 5). By contrast, the binding of BC3 antibody
(anti-HMFG) was enhanced by neuraminidase treatment in
all five breast carcinomas (Figure 5); the binding of BC2
antibody (anti-HMFG) was similarly enhanced by neur-
aminidase treatment (data not shown). These results suggest
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Figure 4 Effect of periodate on the 3E1.2 defined antigen
(MSA). Membrane preparations of ZR75 breast cancer cells were
treated with (A) PBS; (B) sodium acetate buffer pH4.5; or
periodate; (C) lOmM, (D) 30mM, (E) 50mM. The reactivities of
the treated preparations with antibody 3E1.2 were then tested in
an ELISA binding assay. (A) and (B) serve as controls.
3E1.2
that sialic acid is required for binding of 3E1.2 antibody,
and epitopes for BC2 and BC3 antibodies (anti-HMFG)
were further exposed by removal of sialic acid.
Ana/isis of AMSA bh, gel filtration (chronlatograplhv
3E1.2 antigen (MSA) has been found to bind the lectin
WGA (wheat germ agglutinin) and the MSA activity of
fractions eluted with N-acetyl glucosamine determined in the
MSA inhibition assay (data not shown). The MSA isolated
from serum by 3E1.2 immunoaffinity chromatography and
WGA lectin affinity chromatography was subjected to gel
filtration chromatography on a Sepharose-6B column to
detcrmine its Mr in the absence of SDS. Fractions eluted
from the column were analysed for their reactivity with
antibody 3EL.2 by the inhibition assay; using either antibody
3E1.2 or lectin affinity chromatography, the activity was
confined to the material (MSA) eluted between the molecular
weight markers blue dextran (2 x 106) and thyroglobulin
(669,000). This suggests that stable MSA aggregates exist
under non-denaturing conditions and such aggregation may
confer stability to the MSA molecule. In addition, the
binding of MSA to lectin WGA suggests that MSA contains
exposed N-acetylneuraminic acid and /3(l-4)-N-acetyl glucos-
amine (Alles et al., 1973; Nagata et al., 1974)
Binding of 3E1.2 to components of humenan milk/
Given that many other monoclonal antibodies to higlh
molecular weight breast cancer associated antigens cross-
react with components of human milk, it was important to
determine if the epitope detected by 3E1.2 was also
expressed on components of human milk. A binding
experiment with HMFGM (Figure 6a) showed that antibody
3E1.2 and a control antibody (5C1) had no or minimal
reactivity with HMFGM, but antibodies HMFG-l and BC3,
known to detect a high molecular weight glycoprotein if
HMFGM (Burchell et al., 1983; unpublished observations),
were found to bind at a much lower concentration than
3E1 .2. Since the cross-reactive molecule in HMFGM has
also been reported in skimmed milk, samples of fresh whole
milk were analysed by SDS-PAGE and tested by immuno-
BC3
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b
Figure 5 Sections of breast carcinoma stained by immunoperoxidase staining with antibodies 3EI.2 or BC3. Countcrstained with
haematoxylin ( x 100). (a) without neuraminidase (NE) treatment; (b) with NE treatment.
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blotting (Figure 6b). Antibody 3E1.2 showed no detectable
reactivity with any components of human milk (Figure 6b,
track A), but antibody 41.3 (anti-HMFG) detecting the high
molecular weight glycoprotein gave a clear reactivity with
these components (Figure 6b, track B). To determine if the
epitope detected by 3E1.2 was masked by carbohydrate on
HMFGM, deglycosylated HMFGM glycoproteins were
prepared and tested in the solid phase binding assay. 3E1.2
was non-reactive with both glycosylated HMFGM and de-
glycosylated HMFGM; in contrast, antibody BC3 (IgM),
known to detect a high molecular weight glycoprotein of
HMFGM, bound to both glycosylated and deglycosylated
HMFGM (full data not shown). Similarly, the reactivity of
antibody HMFG-1 with both glycosylated and deglycosyl-
ated HMFGM had been previously noted (Burchell et al.,
a
1 E
1987). These experiments clearly show the absence of the
epitope detected by monoclonal antibody 3E1.2 on
components of human milk. However, as antibody 3E1.2
bound poorly to milk-derived mucin (Figure 6), rigorous
testing of whether antibody 3E1.2 binds core protein may
require purification and deglycosylation of mucin from
sources which react with the 3E1.2 antibody.
Digestion of MSA and PAS-O with proteases
Limited proteolytic digestion of SDS-PAGE purified MSA
with a panel of proteases showed that the molecules detected
by antibody 3E1.2 were resistant to digestion with trypsin,
Staphylococcus aureus V8 protease and thermolysin but
sensitive to proteinase K (Figure 7a), pronase and subtilisin
a A B C DEti'd'WA
: r
' .e, ;.,,..*iv..
'*..l.S|
30 15 7.5 3.75 1.88 0.94 0.47 0.24
Antibody concentration p.g ml-1
b
Mr (X 103)
A B C
b
Undigested Pronase Subtilisin .
E. 0 f '. 'uM'
<. Is < .
~ ~ <0 .
1 I-
1 - -- " -
*_-
97-
68- 200-
43-
116-
31-
22- 66-
Figure 6 Reactivity of monoclonal antibody 3E1.2 with
components of human milk. (a) Solid phase binding study
showing binding of HMFG-1, BC3, 3E1.2 and control antibody
(5C1) to preparations of human milk fat globule membrane; (b)
whole human milk was fractionated on a 5% SDS
polyacrylamide gel, transferred to nitrocellulose and probed with
monoclonal antibodies (A) 3E1.2, (B) 41.3 (anti-HMFG), (C)
anti-CD8 antibody (negative control). Approximate molecular
weight markers are indicated.
Figure 7 Analysis of 125I-labelled MSA and PAS-O after
proteolytic digestion by SDS-PAGE and autoradiography. (a)
Gel purified MSA was subjected to limited proteolytic digestion
with 10 ugml-1 of the following proteases: (A) trypsin, (B)
Staphylococcus aureus V8 protease, (C) thermolysin and (D)
proteinase K for 4h at 37°C; (b) Gel purified BSA, MSA and
PAS-O were subjected to limited proteolytic digestion with
5pgml 1 of subtilisin and pronase. Identical amounts (c.p.m.) of
radiolabelled MSA and PAS-O were loaded in each track.
Molecular weight markers, shown as daltons x 103 , are as
follows: phosphorylase b (97), bovine serum albumin (66),
ovalbumin (43), carbonic anhydrase (31) and soybean trypsin
inhibitor (22).
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(Figure 7b). MSA was also subjected to digestion with a
large excess of trypsin, Staphylococcus aureus V8 protease
and thermolysin (250yugml-1) for 16h at 37°C with identical
results (data not shown). To investigate the relationship
between MSA and the high molecular weight glycoprotein of
human milk (PAS-O), proteolytic digestion was performed
using the enzymes pronase and subtilisin on gel purified
MSA and PAS-O (Figure 7b). The subtilisin digest of MSA
contained a cluster of glycopeptide bands of M, values
60,000-100,000. These bands were absent in the
corresponding PAS-O channel. However, it cannot be
confidently concluded that this disparity is due solely to
differences in the polypeptide backbones of the two
structures since differential glycosylation might also
contribute to the different patterns of proteolytic digestion of
MSA and PAS-O.
Multiple epitope expression on MSA
MSA eluted from a 3EI.2 immunoaffinity column was tested
for its reactivity with a number of monoclonal antibodies
which detect epitopes known to be expressed on PAS-O of
HMFGM and the high molecular weight glycoproteins seen
in the serum of patients with breast cancer. Antibodies DF3
and BC3 (anti-HMFG) were tested for their reactivity on
MSA by immunoblotting (Figure 8). Both antibodies reacted
with MSA, indicating that their epitopes are present on some
or all 3E1.2+ molecules. Antibodies 41.3 and 4B6.1, directed
to glycoprotein PAS-O of human milk also reacted with
MSA (data not shown). These studies indicate that the MSA
molecule contains a significant number of epitopes in
common with PAS-O and the high molecular weight glyco-
protein previously described in breast cancer.
As shown in Table I, using a sandwich immunoassay,
when hybridoma ascitic fluids were adsorbed to the wells of
PVC plates and then treated with MSA, purified from
serum, there was subsequent significant binding of 125J1
labelled 3E1.2 antibody only in wells coated with 3E1.2 and
BC3 antibodies but not in wells coated with control antibody
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Figure 8 Immunoblotting of MSA obtained from the immuno-
affinity column with antibodies DF3, BC3 and control antibody
(5Cl). Blots were autoradiographed as described. Molecular
weight markers are indicated.
Table I Sandwich immunoassay for the analysis of epitopes on
3E1.2 defined antigen
Binding of 12 II-3EL.2
(mean c.p.m. +s.d. X 102)
bound to hybridoma ascitic
Hybridoma ascitic fluid fluid coated wells treated with
(1/500) adsorbed to wells Buffer MSA
3E1.2 1+1 52+4
BC3 (anti-HMFG) 2+0 28+3
5C1 (control antibody) 2+0 3+1
(5C1). This indicates that the MSA expresses repeated 3E1.2
defined epitopes and the experiment confirms the co-
expression of 3E1.2 and BC3 epitopes on at least a
proportion of the MSA molecules.
Discussion
Monoclonal antibody 3EI.2 was produced against a primary
carcinoma of the breast, and detects a breast cancer
associated antigen present in human serum called mammary
serum antigen (MSA) (Stacker et al., 1985; Tjandra et al.,
1988). Studies have shown that MSA is elevated in the sera
of a high proportion of patients with breast cancer,
compared to normal individuals, and that the levels are
useful for monitoring patients with breast cancer (Stacker et
al., 1987; Tjandra et al., 1988). Using the sera from patients
with advanced breast cancer as a source of antigen, MSA
was isolated using immunoaffinity chromatography and a
solid phase immunoprecipitation technique. Subsequent
SDS-PAGE and immunoblotting analysis showed the
antigenic determinants for antibody 3E1.2 reside on hetero-
geneous molecules of Mr300,000-400,000. These molecules
stained pQorly with Coomassie blue but stained well in a
PAS-silver stain and they bound the lectin WGA (data not
shown), indicating the glycoprotein nature of MSA. The
high molecular weight of MSA was confirmed by gel
filtration chromatography of material eluted from a 3EI.2
affinity column and a WGA affinity column. There was a
difference between the native (Mr=0.7-2.0 x 106) and
apparent '(Mr 300,000) molecular weights. Whether the
larger molecules arise by spontaneous association of
monomers or through link proteins is not clear (Wesley et
al., 1985; Pearson et al., 1981).
The results of the immunoblotting tests indicate that 3E1.2
defined antigen (MSA) from serum, ascites or breast car-
cinoma of the same patient displayed similar mobility in
SDS-PAGE gels. In addition, the antigens purified from
different sources had strong inhibitory activity when tested
in the MSA inhibition assay. It appears that 3E1.2 defined
antigen (MSA) can be released from breast carcinoma to the
circulation and also locally into the ascites. The level of
MSA in the circulation has been shown to depend on the
tumour burden and tumour grade but is also dependent on
some other factors as yet unidentified, as some cases of
carcinoma in situ had elevated circulating MSA level
(Tjandra et al., 1988; Hare et al., 1988).
Studies by other workers have also demonstrated the
existence of high molecular weight glycoproteins on human
breast cancer cells (Ashall et al., 1982; Burchell et al., 1984;
Linsley et al., 1986; Ormerod et al., 1983; Papsidero et al.,
1984a; Price et al., 1985; Sekine et al., 1985) and in the
serum of patients with breast cancer (Hayes et al., 1985;
Hilkens et al., 1986; Burchell et al., 1984; Linsley et al.,
1986; Papsidero et al., 1984b). A number of these molecules
are also related to the PAS-O glycoprotein found on the
human milk fat globule and the epithelial membrane antigen
(EMA) found in human milk (Shimizu et al., 1982; Ormerod
et al., 1985), which is not surprising since many of the
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antigens were originally produced against components of
human milk (Arklie et al., 1981; Hilkens et al., 1984). Apart
from having a similar tissue distribution (restricted mainly to
secretory epithelium), these high molecular weight breast
cancer associated antigens share a number of common
biochemical features. Firstly, these antigens are high
molecular weight mucin-like glycoproteins, in which the
majority of carbohydrate is joined to the peptide core by 0-
glycosidic linkages. The molecular weights were variously
reported as >300,000, but in most cases in the region of
300,000-400,000 by SDS-PAGE analysis (Abe et al., 1987).
Secondly, the molecules have a high content of
carbohydrate, indicated by poor staining with conventional
protein stains, but strong staining with specific carbohydrate
stains, and by the binding of specific lectins, usually WGA
and peanut agglutinin (PNA) (Burchell et al., 1983; Ormerod
et al., 1983; Sekine et al., 1985). Thirdly, the molecules are
resistant to digestion by many commonly used proteases, but
digestion by pronase and subtilisin, proteases which catalyse
the hydrolysis of a wide variety of peptide bonds, have been
reported (Sekine et al., 1985; Shimizu et al., 1982). Finally,
many of the monoclonal antibodies that define these
molecules in patients with breast cancer react with the
glycoproteins PAS-O or EMA (epithelial membrane antigen)
in human milk which also possess these biochemical features.
Thus, these breast cancer associated antigens and normal
glycoproteins of human milk may constitute a family of
related molecules.
Clearly, as part of this study it was important to
determine the relationship of MSA to these high molecular
weight glycoproteins. The biochemical characteristics of
MSA are similar to those of the above mentioned molecules
in a number of ways: similar high molecular weight glyco-
proteins (Mr by SDS-PAGE>300,000), binding of WGA
lectin and susceptibility to attack by subtilisin and pronase.
It was also shown that monoclonal antibodies to PAS-O and
other high molecular weight glycoproteins of breast cancer
also react with MSA. This implies that a number of
epitopes, presumably carbohydrate or carbohydrate-protein
epitopes, are shared between PAS-O and MSA, and is
evidence to suggest that PAS-O and MSA may possess
similar or identical polypeptide backbones or distinct poly-
peptide chains with similar carbohydrate side chains. There
are, however, several properties which suggest that mono-
clonal antibody 3E1.2 defines a unique epitope, in particular
the lack of or limited binding of 3E1.2 to components of
human milk, HMFGM and deglycosylated HMFGM.
However, it has been shown that relative levels of binding of
antibodies HMFG-1 and HMFG-2 varied between cell lines
from normal and malignant breast epithelium, with the
HMFG-2 epitope being expressed more strongly on tumour
cell lines (Burchell et al., 1983). Likewise, antibody W5
bound more strongly to WI affinity-purified mucin from
milk than to mucin purified from serum of breast cancer
patients (Linsley et al., 1986). These observations indicate
that mucins from different sources may vary antigenically
and could account for the lack of or limited binding of
antibody 3E1.2 to components of human milk, HMFGM
and deglycosylated HMFGM but strong binding to a
tumour cell line (ZR75) derived mucin (data not shown). In
contrast, antibody BC3 (anti-HMFG) bound more strongly
to a purified milk-derived mucin and deglycosylated
HMFGM than to the tumour cell line (ZR75) derived mucin
(data not shown), suggesting that core protein epitopes may
be masked, modified or otherwise different in mucin glyco-
proteins from different sources (Burchell et al., 1987). In
addition, proteolytic digestion studies of MSA and PAS-O
further suggest the molecular non-identity of these molecules.
However, the effects of different degrees ofglycosylation and
the size or charge of peptide fragments and the accessibility of proteases preclude the firm interpretation that the
differences between the molecules occur at the level of their
respective polypeptide backbones. Therefore, at the very least, antibody 3E1.2 defines a unique epitope on a high
molecular weight glycoprotein present in serum, ascites and
breast carcinoma tissue but absent or present in very low
amounts in milk. In addition, the reduced binding of anti-
body 3E1.2 upon periodate oxidation suggests that the
epitope defined by antibody 3E1.2 involves carbohydrate.
Since periodate oxidation of the antigen did not completely
abolish the binding of antibody 3E1.2, a contribution by the
protein backbone to the epitope cannot be excluded. Because
of the high degree of glycosylation of mucin glycoproteins, it
seemed likely that epitopes for many mucin directed
antibodies would contain oligosaccharide structures. In
addition, binding of 3E1.2 antibody was neuraminidase
sensitive, suggesting that sialic acid is required for binding of
this antibody.
The heterogeneity seen with these high molecular weight
glycoproteins indicates that they constitute a family of
related molecules. Recent studies by other workers (Griffiths
et al., 1987; Ormerod et a4, 1985; Price et al., 1985, 1986)
have shown that epitopes for a number of monoclonal
antibodies reactive with high molecular weight glycoproteins
of breast cancer are present on antigen preparations purified
by monoclonal antibodies NCRC-11 and HMFG-2
respectively. In addition, antigen purified from human breast
tumour cells and human milk by antibody DF3 has been
shown to bind other monoclonal antibodies F36/22 and Cal
(Abe et al., 1987); further evidence for a family of related
high molecular weight tumour associated glycoproteins. In
this study, antibodies DF3 and BC3 were shown to bind
purified MSA, thereby confirming a relationship between
MSA and the other high molecular weight glycoproteins of
human milk and breast cancer. Antibody DF3 is now known
to react with a core protein epitope (Siddiqui et al., 1988)
and has been used to clone the same cDNA as was cloned
by Gendler et al. (1988) using other antibodies (HMFG-1,
HMFG-2 and SM-3). These data indicate that there is
clearly a family of related molecules, each of which probably
has the same core protein. Thus, it is possible that the 3E1.2
defined antigen (MSA) shares the same or similar core
protein as DF3 defined antigen. It has been shown indirectly
for the polymorphic epithelial mucin or PEM (Burchell et
al., 1983) and directly for the DF3 purified antigen (Hull et
al., 1988) that the glycosylation is different in normal (the
carbohydrate component was analysed by Shimizu &
Yamauchi (1982)) and cancer associated mucin. Thus both
core protein and carbohydrate epitopes can be identified on
the cancer associated PEM mucin which are not found, or to
a much lesser degree on the normally processed mucin as in
HMFGM. It appears that oligosaccharide structures are
important components of the 3E1.2 defined epitope which is
closely tumour related. Determining the exact relationship of
these molecules will involve further studies examining the
primary polypeptide structure and oligosaccharide moieties
of this group of molecules.
Polymorphism was also seen in the MSA molecules
obtained from different patients (Figure 3), as shown by the
difference in mobilities of 3E1.2 reactive high molecular
weight components in polyacrylamide gels. These differences
could be due to either genetically determined allelic
differences in the protein or carbohydrate portions of the
molecules, or by the modification of sugar residues after
cellular expression or secretion. In this context we note
recent studies describing the genetic polymorphism of a
urinary mucin-type glycoprotein related to the mucin glyco-
protein of mammary tumours and human milk which defines
a gene locus (PUM), with at least ten alleles which determine
the expression of ten defined specificities (Gendler et al.,
1987; Swallow et al., 1987). In the light of the relationship
between MSA and the high molecular weight glycoproteins
of human milk, a similar system could control the expression
of MSA.
In summary, this study has shown that monoclonal anti-
body 3E1.2 defines a high molecular weight glycoprotein
(MSA) in the serum, ascites and breast cancer tissue of
patients with breast cancer. The 3E1.2 defined antigen552 S.A. STACKER et al.
(MSA) appears to be related to a discrete family of high
molecular weight glycoproteins defined in breast cancer
patients sharing a number of common biochemical features
and antigenic epitopes; however, monoclonal antibody 3E1.2
detects an epitope not expressed by PAS-O of human milk,
making it a unique variant.
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